Heli Huang
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)Pfizer (United States)(US)Pear Therapeutics (United States)(US)Cellerant Therapeutics (United States)(US)
Publications by Year
Research Areas
Cancer, Hypoxia, and Metabolism, Epigenetics and DNA Methylation, RNA modifications and cancer, Cancer therapeutics and mechanisms, Lung Cancer Research Studies
Most-Cited Works
- → 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma(2019)202 cited
- → Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate (S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385)(2018)110 cited
- → 14-Aminocamptothecins: Their Synthesis, Preclinical Activity, and Potential Use for Cancer Treatment(2011)21 cited
- → Exploring the Effectiveness of Project-Based Learning on Speaking Test Performance(2022)3 cited
- → Abstract B140: PT2977, a novel HIF-2a antagonist, has potent antitumor activity and remodels the immunosuppressive tumor microenvironment in clear cell renal cell cancer(2018)3 cited